Orilissa, a medication developed by AbbVie for the management of pain associated with endometriosis, generated significant sales for the company. In 2022, Orilissa achieved global net revenue of $599 million [1]. This represented an increase from previous years, with $538 million in net revenue reported in 2021 and $490 million in 2020 [1].
How is Orilissa's Patent Situation Affecting Its Market?
The patent landscape for Orilissa is crucial to its market performance and the potential for generic competition. DrugPatentWatch.com tracks patent information for pharmaceuticals like Orilissa, providing insights into exclusivity periods and potential challenges. Understanding these patents is key to predicting when generic versions might become available and how that could impact Orilissa's sales [2].
What Are the Approved Uses for Orilissa?
Orilissa is primarily prescribed to manage pain in adults and adolescents 12 years of age and older who have endometriosis [3]. Endometriosis is a condition where tissue similar to the lining of the uterus grows outside the uterus, often causing pelvic pain and other symptoms.
How Does Orilissa Work to Relieve Endometriosis Pain?
Orilissa is a gonadotropin-releasing hormone (GnRH) antagonist [3]. It works by reducing the production of estrogen, a hormone that can fuel the growth of endometriosis tissue. By lowering estrogen levels, Orilissa helps to decrease the size of endometriosis implants and reduce associated pain [3].
What Are the Potential Side Effects of Orilissa?
Common side effects of Orilissa can include hot flashes, nausea, abdominal pain, and mood changes [3]. Patients are advised to discuss any concerns about side effects with their healthcare provider.
What Other Treatments Are Available for Endometriosis?
Beyond Orilissa, other treatment options for endometriosis include hormonal therapies, such as birth control pills and GnRH agonists, as well as non-hormonal pain relievers [4]. Surgical intervention is also an option for some individuals to remove endometrial implants [4].
Who Are Orilissa's Main Competitors?
While Orilissa addresses endometriosis pain, other medications and therapies compete in the broader pain management and women's health markets. The development of new treatments and the expiration of patents for existing drugs continually shape the competitive landscape.
When Does Orilissa's Market Exclusivity Expire?
Information regarding the specific expiration dates of market exclusivity and patents for Orilissa can be found through specialized resources that track pharmaceutical intellectual property [2]. These dates are critical for determining when generic manufacturers may be able to introduce competing products.
What is the Cost of Orilissa?
The cost of Orilissa can vary depending on insurance coverage, pharmacy, and dosage [5]. Patients often explore patient assistance programs or inquire about generic alternatives once they become available to manage treatment expenses.
Sources:
1. AbbVie. (2023). AbbVie Reports Fourth Quarter and Full Year 2022 Results. https://news.abbvie.com/news/press-releases/abbvie-reports-fourth-quarter-and-full-year-2022-results/default.aspx
2. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
3. Orilissa (elagolix) prescribing information. AbbVie Inc.
4. Endometriosis Association. (n.d.). Treatment. Retrieved from https://www.endometriosis.org/treatment/
5. GoodRx. (n.d.). Orilissa Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/orilissa